WeVote
Log In

Bill

WeVote Research Nonpartisan
Bill Summary · SB 2038

Legislative bill overview

SB 2038 addresses medication labeling requirements in Hawaii, though the specific provisions are not detailed in the available information. The bill was introduced in January 2026 and referred to the Health and Human Services committee for consideration. As of late January 2026, the HHS committee deferred the measure, indicating it requires further deliberation before advancement.

Why is this important

Medication labeling standards directly affect patient safety, medication adherence, and healthcare outcomes. Clear, accurate labeling helps prevent medication errors, drug interactions, and adverse effects—particularly important for vulnerable populations like the elderly or those with multiple prescriptions. Hawaii's specific approach could serve as a model for other states or influence how pharmacies and manufacturers operate within the state.

Potential points of contention

  • Industry compliance costs: Manufacturers and pharmacies may face expenses to redesign labels, update printing systems, or reformulate labeling processes, potentially affecting smaller operations disproportionately
  • Consumer readability vs. completeness: Balancing comprehensive medical information with font sizes and language clarity that actual patients can understand—too much detail overwhelms users; too little creates safety gaps
  • Regulatory scope and enforcement: Unclear whether the bill applies only to Hawaii-dispensed medications, imported drugs, or all medications sold in-state, and which agency bears enforcement responsibility

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.